COST EFFECTIVENESS ANALYSIS OF EVOLOCUMAB, A PCSK9 INHIBITOR, FROM THE US SOCIETAL PERSPECTIVE

被引：0
|
作者：
Innis, B. D. [1 ]
Hay, J. W. [1 ]
机构：
[1] Univ Southern Calif, Los Angeles, CA USA
来源：
VALUE IN HEALTH | 2018年 / 21卷
关键词：
D O I：
10.1016/j.jval.2018.04.368
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCV46
引用
收藏
页码：S60 / S61
页数：2
相关论文
共 50 条
  • [1] Cost-effectiveness of PCSK9 Inhibitor Therapy
    Mastey, Vera
    Johnstone, Bryan M.
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2016, 316 (20): : 2151 - 2152
  • [2] Clinical Pharmacokinetics and Pharmacodynamics of Evolocumab, a PCSK9 Inhibitor
    Kasichayanula, Sreeneeranj
    Grover, Anita
    Emery, Maurice G.
    Gibbs, Megan A.
    Somaratne, Ransi
    Wasserman, Scott M.
    Gibbs, John P.
    CLINICAL PHARMACOKINETICS, 2018, 57 (07) : 769 - 779
  • [3] Clinical Pharmacokinetics and Pharmacodynamics of Evolocumab, a PCSK9 Inhibitor
    Sreeneeranj Kasichayanula
    Anita Grover
    Maurice G. Emery
    Megan A. Gibbs
    Ransi Somaratne
    Scott M. Wasserman
    John P. Gibbs
    Clinical Pharmacokinetics, 2018, 57 : 769 - 779
  • [4] Cost-effectiveness of PCSK9 Inhibitor Therapy In Reply
    Kazi, Dhruv S.
    Moran, Andrew E.
    Bibbins-Domingo, Kirsten
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2016, 316 (20): : 2152 - 2152
  • [5] PCSK9 inhibition: from effectiveness to cost-effectiveness
    Mercep, Iveta
    Strikic, Dominik
    Hrabac, Pero
    Pecin, Ivan
    Reiner, Zeljko
    FRONTIERS IN CARDIOVASCULAR MEDICINE, 2024, 11
  • [6] The cost-effectiveness of PCSK9 inhibitors - The Australian healthcare perspective
    Kumar, Radya
    Tonkin, Andrew
    Liew, Danny
    Zomer, Ella
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2018, 267 : 183 - 187
  • [7] Efficacy and Safety of the PCSK9 Inhibitor Evolocumab in Patients with Mixed Hyperlipidemia
    Rosenson, Robert S.
    Jacobson, Terry A.
    Preiss, David
    Djedjos, C. Stephen
    Dent, Ricardo
    Bridges, Ian
    Miller, Michael
    CARDIOVASCULAR DRUGS AND THERAPY, 2016, 30 (03) : 305 - 313
  • [8] Efficacy and Safety of the PCSK9 Inhibitor Evolocumab in Patients with Mixed Hyperlipidemia
    Robert S. Rosenson
    Terry A. Jacobson
    David Preiss
    C. Stephen Djedjos
    Ricardo Dent
    Ian Bridges
    Michael Miller
    Cardiovascular Drugs and Therapy, 2016, 30 : 305 - 313
  • [9] EVOLOCUMAB, A PCSK9 INHIBITOR, SUPPRESSES ABDOMINAL AORTIC ANEURYSM PROGRESSION IN MICE
    Park, S. -H.
    Park, E. -H.
    Lee, E.
    Kim, E.
    Kim, J. -M.
    Kim, C. W.
    Oak, M. -H.
    Choi, I. J.
    Chang, K.
    ATHEROSCLEROSIS, 2023, 379
  • [10] Evolocumab (Repatha) A Second PCSK9 Inhibitor to Lower LDL-Cholesterol
    不详
    MEDICAL LETTER ON DRUGS AND THERAPEUTICS, 2015, 57 (1479): : 139 - 140
12345